Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity.
Our laboratory has synthesized two new phenolic thioether amines, N-propionyl-4-S-cysteaminylphenol (N-Pr-4-S-CAP) and N[2-[(4-propionyloxyphenyl)thio]ethyl] propionamide (N,O-diPr-4-S-CAP). These compounds, along with the previously described phenolic thioether amine N-acetyl-4-S-cysteaminylphenol (N-Ac-4-S-CAP) and its acetyl form (N,O-diAc-4-S-CAP), are tyrosine-amine derivative analogues. The cytotoxicity of these compounds is thought to be tyrosinase dependent, which may make them suitable for targeted anti-melanoma therapy since only melanocytes and their malignant counterparts contain this active enzyme. To further investigate this hypothesis, we performed MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] assays to determine the cytotoxicity of these compounds in 10 different cell lines. Specifically, we examined to what extent cytotoxicity is related to tyrosinase and tyrosine hydroxylase activity using melanoma and neuroblastoma cells, which have a common metabolic pathway using tyrosinase and tyrosine hydroxylase, respectively. The most sensitive cell line was the highly pigmented SK-MEL-23 melanoma cell line, which shows a very high tyrosinase activity with the highest melanin pigmentation. KAN and SK-NSH (two neuroblastoma cell lines), which have no tyrosinase activity but high tyrosine hydroxylase, were also sensitive. However, C32 (a non-pigmented melanoma with a lower tyrosinase activity) was also sensitive, and MeWo (a moderately pigmented melanoma with a high tyrosinase activity) was less sensitive. This in vitro study may indicate that there is a non-tyrosinase-mediated mechanism of cytotoxicity for phenolic thioether amines in addition to the tyrosinase-mediated one described previously.
Gili
A
A
Faculty of Medicine, Division of Dermatology and Cutaneous Sciences, University of Alberta, Edmonton, Canada.
Thomas
P D
PD
Ota
M
M
Jimbow
K
K
D000577:Amides / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D003538:Cystamine / Q000031:analogs & derivatives* / Q000633:toxicity; D003543:Cysteamine / Q000031:analogs & derivatives* / Q000633:toxicity; D006131:Growth Inhibitors / Q000633:toxicity; D006367:HeLa Cells; D006801:Humans; D008545:Melanoma / Q000201:enzymology / Q000473:pathology*; D014442:Monophenol Monooxygenase / Q000378:metabolism*; D009447:Neuroblastoma / Q000201:enzymology / Q000473:pathology*; D010636:Phenols / Q000633:toxicity*; D014407:Tumor Cells, Cultured; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
D000577:Amides; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; C406027:N-(2-((4-propionyloxyphenyl)thio)ethyl) propionamide; C114098:N-propionyl-4-S-cysteaminylphenol; D010636:Phenols; D003543:Cysteamine; C066420:N-acetyl-4-S-cysteaminylphenol; D014446:Tyrosine 3-Monooxygenase; D014442:Monophenol Monooxygenase; D003538:Cystamine